Condition: B-cell Non Hodgkin Lymphoma · Sponsor: Taiho Oncology, Inc.
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
This description comes directly from the study's public registry record.
Taiho Oncology, Inc. · +1 844-878-2446 · ABLATE-101@taihooncology.com
Always discuss trial participation with your own doctor first.
| Start Cala | Los Angeles, California, United States | Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Not Yet Recruiting |
| NYU Langone | New York, New York, United States | Not Yet Recruiting |
| Levine Cancer Institute | Charlotte, North Carolina, United States | Not Yet Recruiting |
| Massey Cancer Center | Richmond, Virginia, United States | Not Yet Recruiting |
| Summit Cancer Centers - North Spokane | Spokane, Washington, United States | Recruiting |
| Froedtert & Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Not Yet Recruiting |
| Monash Health | Clayton, Australia | Not Yet Recruiting |
| Austin Health | Melbourne, Australia | Not Yet Recruiting |
| Linear Clinical Research | Nedlands, Australia | Not Yet Recruiting |
| Gold Coast Hospital | Southport, Australia | Not Yet Recruiting |
| Hopital Henri-Mondor | Créteil, France | Not Yet Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07691606